Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Sigyn Therapeutics, Inc. (SIGY) had Return on Tangible Equity of 13.52% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.67M |
|
-- |
|
-- |
|
$0.55M |
|
$-0.55M |
|
$-0.12M |
|
$-0.67M |
|
$-0.67M |
|
$-0.67M |
|
$-0.67M |
|
$-0.67M |
|
$-0.67M |
|
$-0.55M |
|
$-0.52M |
|
1.61M |
|
1.61M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$0.07M |
|
$0.01M |
|
$0.18M |
|
$0.24M |
|
$5.15M |
|
-- |
|
$0.04M |
|
$5.19M |
|
$-4.95M |
|
$-4.95M |
|
$-4.95M |
|
1.60M |
|
| Cash Flow Statement Financials | |
$-0.29M |
|
-- |
|
$0.30M |
|
$0.01M |
|
$0.01M |
|
$0.00M |
|
$0.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.01 |
|
-- |
|
-- |
|
-- |
|
-0.49 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
13.52% |
|
|
Return on Tangible Equity |
13.52% |
-273.66% |
|
13.52% |
|
$-3.08 |
|
$-0.18 |
|
$-0.18 |
|